PE20100371A1 - Agonistas del receptor s1p para el tratamiento de malaria cerebral - Google Patents
Agonistas del receptor s1p para el tratamiento de malaria cerebralInfo
- Publication number
- PE20100371A1 PE20100371A1 PE2009001210A PE2009001210A PE20100371A1 PE 20100371 A1 PE20100371 A1 PE 20100371A1 PE 2009001210 A PE2009001210 A PE 2009001210A PE 2009001210 A PE2009001210 A PE 2009001210A PE 20100371 A1 PE20100371 A1 PE 20100371A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- cerebral malaria
- receptor agonists
- formulation
- receptor
- Prior art date
Links
- 206010063094 Cerebral malaria Diseases 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 abstract 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 abstract 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 abstract 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 abstract 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract 1
- 235000001258 Cinchona calisaya Nutrition 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229940079172 Osmotic diuretic Drugs 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001754 anti-pyretic effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 239000002221 antipyretic Substances 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229960000556 fingolimod Drugs 0.000 abstract 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002337 osmotic diuretic agent Substances 0.000 abstract 1
- 229960005489 paracetamol Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960001404 quinidine Drugs 0.000 abstract 1
- 229960000948 quinine Drugs 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA QUE CONTIENE: A) UN AGONISTA DEL RECEPTOR DE LA ESFINGOSINA-1-FOSFATO (S1P) DE FORMULA (I) DONDE Rp ES FENILO SUSTITUIDO CON ALQUILO(C6-C18), CICLOALQUILO, HETEROARILO O HETEROCICLO, EN DONDE UN COMPUESTO PREFERIDO ES FTY720; Y B) UNA AGENTE ACTIVO ADICIONAL TALES COMO i) UN FARMACO ANTIMALARIA TAL COMO QUININA, QUINIDINA, ENTRE OTROS, ii) UN DIURETICO OSMOTICO TAL COMO MANITOL, UREA, ENTRE OTROS, iii) UN ANTICONVULSIVANTE TAL COMO DIAZEPAN, FENITOINA, FENOBARBITAL, ENTRE OTROS, iv) UN ANTIPIRETICO TAL COMO PARACETAMOL, v) UN ANTIOXIDANTE, O vi) UN ANTIINFLAMATORIO. DICHA FORMULACION SE PRESENTA COMO UNA FORMA DE DOSIFICACION PARA SU ADMINISTRACION TOPICA, TRANSDERMICA O INTRAVENOSA SIENDO UTIL EN EL TRATAMIENTO DE LA MALARIA CEREBRAL
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10999108P | 2008-10-31 | 2008-10-31 | |
| US22997009P | 2009-07-30 | 2009-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20100371A1 true PE20100371A1 (es) | 2010-06-01 |
Family
ID=41621568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009001210A PE20100371A1 (es) | 2008-10-31 | 2009-10-28 | Agonistas del receptor s1p para el tratamiento de malaria cerebral |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100112037A1 (es) |
| EP (1) | EP2349334A1 (es) |
| JP (1) | JP2012507546A (es) |
| CN (1) | CN102196820A (es) |
| AR (1) | AR074062A1 (es) |
| AU (1) | AU2009308843A1 (es) |
| CA (1) | CA2741546A1 (es) |
| CL (1) | CL2009002017A1 (es) |
| PE (1) | PE20100371A1 (es) |
| TW (1) | TW201021790A (es) |
| UY (1) | UY32214A (es) |
| WO (1) | WO2010051349A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011159864A1 (en) * | 2010-06-17 | 2011-12-22 | Bracco Imaging S.P.A. | Jte013 analogs and methods of making and using same |
| WO2012071278A1 (en) * | 2010-11-22 | 2012-05-31 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
| WO2015053878A1 (en) * | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
| JP6618191B2 (ja) * | 2014-03-27 | 2019-12-11 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 脳マラリアの診断および治療 |
| JP6833855B2 (ja) | 2015-12-30 | 2021-02-24 | コリウム， インコーポレイテッド | 長期間経皮投与のためのシステムおよび方法 |
| EP3474831A1 (en) | 2016-06-23 | 2019-05-01 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
| MX2019001104A (es) | 2016-07-27 | 2019-10-02 | Corium Int Inc | Sistemas de suministro transdermico de memantina. |
| KR102406482B1 (ko) | 2016-07-27 | 2022-06-08 | 코리움, 인크. | 염 약물의 염 약물에서 중성 약물으로의 제자리 전환에 의한 저용해도 또는 불안정한 이온화되지 않은 중성 약물의 경피성 제제 및 전달 방법 |
| EP3490559A1 (en) * | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
| US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| WO2019245512A2 (en) * | 2018-06-21 | 2019-12-26 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A combination comprising fingolimod and at least one anti-epileptic agent |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0627406T3 (da) * | 1992-10-21 | 1999-07-12 | Taito Co | 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler |
| CA2539033C (en) * | 2003-09-12 | 2013-03-05 | Neuronova Ab | Treatment of disease or injury of the nervous system with fty720 |
| GB0411929D0 (en) * | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
| US7649098B2 (en) * | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
| SG174029A1 (en) * | 2006-08-08 | 2011-09-29 | Kyorin Seiyaku Kk | Aminoalcohol derivative and immunosuppressant containing the same as active ingredient |
| CL2007003784A1 (es) * | 2006-12-21 | 2008-06-27 | Abbott Lab | Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato |
| WO2008124210A1 (en) * | 2007-02-14 | 2008-10-16 | Emory University | Methods and compositions for treating or preventing infection using leukocyte sequestration agents |
| UY31013A1 (es) * | 2007-04-12 | 2008-09-02 | Lexicon Pharmaceuticals Inc | Metodos para prepar compuestos basados en imidazol |
| TW200920355A (en) * | 2007-09-06 | 2009-05-16 | Lexicon Pharmaceuticals Inc | Compositions and methods for treating immunological and inflammatory diseases and disorders |
-
2009
- 2009-10-28 PE PE2009001210A patent/PE20100371A1/es not_active Application Discontinuation
- 2009-10-28 AR ARP090104143A patent/AR074062A1/es unknown
- 2009-10-29 JP JP2011534744A patent/JP2012507546A/ja active Pending
- 2009-10-29 US US12/608,332 patent/US20100112037A1/en not_active Abandoned
- 2009-10-29 AU AU2009308843A patent/AU2009308843A1/en not_active Abandoned
- 2009-10-29 CN CN2009801429488A patent/CN102196820A/zh active Pending
- 2009-10-29 CA CA2741546A patent/CA2741546A1/en not_active Abandoned
- 2009-10-29 WO PCT/US2009/062502 patent/WO2010051349A1/en not_active Ceased
- 2009-10-29 EP EP09752585A patent/EP2349334A1/en not_active Withdrawn
- 2009-10-30 UY UY0001032214A patent/UY32214A/es not_active Application Discontinuation
- 2009-10-30 TW TW098136956A patent/TW201021790A/zh unknown
- 2009-10-30 CL CL2009002017A patent/CL2009002017A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010051349A1 (en) | 2010-05-06 |
| US20100112037A1 (en) | 2010-05-06 |
| AR074062A1 (es) | 2010-12-22 |
| CN102196820A (zh) | 2011-09-21 |
| EP2349334A1 (en) | 2011-08-03 |
| CA2741546A1 (en) | 2010-05-06 |
| UY32214A (es) | 2010-05-31 |
| TW201021790A (en) | 2010-06-16 |
| CL2009002017A1 (es) | 2011-01-07 |
| AU2009308843A1 (en) | 2010-05-06 |
| JP2012507546A (ja) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20100371A1 (es) | Agonistas del receptor s1p para el tratamiento de malaria cerebral | |
| UY32602A (es) | Formulación para la administración oral de un promotor de apoptosis | |
| DK201470535A (en) | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof | |
| CR20120663A (es) | Combinaciones que comprenden antisicóticos atípicos y agonistas taar1 | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| MX2018003096A (es) | Composicion farmaceutica que contiene farmaco anionico, y metodo de preparacion para la misma. | |
| MX369117B (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| GT201000095A (es) | Producto de dispersión sólida que contiene un compuesto a base de n-aril urea | |
| CR20140005A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
| BR112015019369A2 (pt) | derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra) | |
| MX2021015654A (es) | Antagonista del receptor 2 de prostaglandina e2 (ep2). | |
| RU2012134065A (ru) | Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления | |
| PE20150345A1 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa 11b-hidroxiesteroide tipo 1 (11b-hsd1) o sal farmaceuticamente aceptable del mismo, metodo para producir el mismo, y composicion farmaceutica que contiene el mismo como ingrediente activo | |
| MX2017016862A (es) | Composicion farmaceutica estable para administracion oral. | |
| DOP2022000107A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| AR095220A1 (es) | Conjunto para un dispositivo de administración de fármacos | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| MX2015010434A (es) | Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo. | |
| AR095194A1 (es) | Conjunto para un dispositivo de administración de fármacos | |
| BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
| MX2019011386A (es) | Compuestos, composiciones farmaceuticas y un metodo para la profilaxis y tratamiento del proceso de adhesion. | |
| AR092719A1 (es) | Metodo y composicion para el tratamiento de ectoparasitos | |
| PE20100372A1 (es) | Inhibidores de la s1p liasa para el tratamiento de malaria cerebral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |